Boruiren Group is an innovative medical group composed of a core management team with rich experience from multinational pharmaceutical companies, invested by a world-renowned capital group.

The group was established in 2019 and is an innovative pharmaceutical enterprise integrating R&D, production, and commercialization platforms. The headquarters are located in Beijing, and advanced biopharmaceutical R&D and production bases are located in Shanghai and Zhuhai. Currently, it has over 2,000 employees nationwide, with a focus on vaccines, pediatrics, orthopedics, cardiovascular and cerebrovascular diseases, neurology, and rare diseases; the marketing team has extensive coverage of over 30,000 hospitals from first-tier cities to county-level cities.

Borealine has a professional and compliant marketing model, the ability to quickly adapt to market changes, innovative medical solutions, and a constant commitment to putting patients first. We strive to provide the most professional full-process medical solutions from diagnosis, treatment, to rehabilitation, using innovative medical products to serve the public health and benefit the people. We aim to help achieve the goal of a healthy China by providing the most professional full-process medical solutions from diagnosis, treatment, to rehabilitation, and innovative medical products.